Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma Corporation (ABUS)
NASDAQ:ABUS
ABUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.30 - $4.73
Previous CloseN/A
Volume149.14K
Average Volume (3M)701.40K
Market Cap
$636.69M
Enterprise Value$606.61M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Feb 27, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding189,491,680
10 Day Avg. Volume665,216
30 Day Avg. Volume701,398
Standard Deviation0.25
R-Squared0.13
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)94.44
Price to Cash Flow (P/CF)-7.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.92
Enterprise Value/Ebitda-8.07
Forecast
1Y Price Target
$5.00Price Target Upside45.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Arbutus Biopharma News
PremiumCompany Announcements
Arbutus Biopharma Highlights Hepatitis B Treatment Advances
PremiumCompany Announcements
Arbutus Biopharma’s Promising cHBV Treatment Results
PremiumCompany Announcements
Arbutus Biopharma’s Trial Boosts Hepatitis B Treatment
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityManagement estimates its cash holdings to sufficiently fund its operations through the first quarter of 2028, allowing for the full funding of the upcoming imdusiran Phase 2b trial.
Therapeutic DevelopmentsAnalyst affirms a buy rating for Arbutus Biopharma, indicating confidence in the company's therapeutic developments.
Bears Say
Legal ChallengesLNP litigation process continues, with ongoing legal challenges against Pfizer/BioNTech and Moderna.
---
Ownership Overview
0.99% Insiders
10.50% Mutual Funds
20.24% Other Institutional Investors
58.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABUS FAQ
What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest stock price was $2.30 and its highest was $4.72 in the past 12 months.
What is Arbutus Biopharma Corporation’s market cap?
Arbutus Biopharma Corporation’s market cap is $636.69M.
When is Arbutus Biopharma Corporation’s upcoming earnings report date?
Arbutus Biopharma Corporation’s upcoming earnings report date is Feb 27, 2025 which is in 5 days.
How were Arbutus Biopharma Corporation’s earnings last quarter?
Arbutus Biopharma Corporation released its earnings results on Nov 06, 2024. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of -$0.094 by -$0.006.
Is Arbutus Biopharma Corporation overvalued?
According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued.
Does Arbutus Biopharma Corporation pay dividends?
Arbutus Biopharma Corporation does not currently pay dividends.
What is Arbutus Biopharma Corporation’s EPS estimate?
Arbutus Biopharma Corporation’s EPS estimate is -0.08.
How many shares outstanding does Arbutus Biopharma Corporation have?
Arbutus Biopharma Corporation has 189,491,680 shares outstanding.
What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
Arbutus Biopharma Corporation reported an EPS of -$0.1 in its last earnings report, missing expectations of -$0.094. Following the earnings report the stock price went down -1.01%.
Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
Currently, no hedge funds are holding shares in ABUS
---
Arbutus Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (45.35% Upside)
$5.00 (45.35% Upside)
Blogger Sentiment
Bullish
ABUS Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.89%
12-Months-Change
Fundamentals
Return on Equity
-67.81%
Trailing 12-Months
Asset Growth
-11.47%
Trailing 12-Months
Company Description
Arbutus Biopharma Corporation
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
---
ABUS Stock 12 Month Forecast
Average Price Target
$5.00
▲(45.35% Upside)
Technical Analysis
Gilead Sciences
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Moderna
―
Best Analysts Covering ABUS
1 Year
1 Year Success Rate
16/32 ratings generated profit
1 Year Average Return
+6.47%
reiterated a buy rating last month
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +6.47% per trade.
---